Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | 12.12% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -28.09% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -36.57% |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 42.23% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 8.71% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 14.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.78% |
| Mar 31, 2026 | 66.11% |
| Dec 31, 2025 | 19.98% |
| Sep 30, 2025 | 45.15% |
| Jun 30, 2025 | 102.96% |
| Mar 31, 2025 | -17.17% |
| Dec 31, 2024 | 152.63% |
| Sep 30, 2024 | 79.35% |
| Jun 30, 2024 | 15.40% |
| Mar 31, 2024 | 10.58% |
| Dec 31, 2023 | -24.84% |
| Sep 30, 2023 | 51.00% |
| Jun 30, 2023 | 6.26% |
| Mar 31, 2023 | -59.37% |
| Dec 31, 2022 | 37.82% |
| Sep 30, 2022 | 8.39% |
| Jun 30, 2022 | -32.56% |
| Mar 31, 2022 | 28.79% |
| Dec 31, 2021 | -33.68% |
| Sep 30, 2021 | -23.76% |